SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies
Accounts of Chemical Research · 17.01.2023 · 56 (2) · 157-168
DOI: 10.1021/acs.accounts.2c00735 ↗Kurz gefasst
Fachartikel in der Zeitschrift Accounts of Chemical Research, online erschienen am 29.12.2022. Verfasst von Bin Tan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United States.
ORCID-Profile: Jun Wang
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Tan, B., Joyce, R., Tan, H., Hu, Y., & Wang, J. (2023). SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies. Accounts of Chemical Research, 56(2), 157-168. https://doi.org/10.1021/acs.accounts.2c00735
Vancouver
Tan B, Joyce R, Tan H, Hu Y, Wang J. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies. Accounts of Chemical Research. 2023;56(2):157-168. doi:10.1021/acs.accounts.2c00735
BibTeX
@article{Tan2023,
author = {Tan, Bin and Joyce, Ryan and Tan, Haozhou and Hu, Yanmei and Wang, Jun},
title = {SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies},
journal = {Accounts of Chemical Research},
year = {2023},
volume = {56},
number = {2},
pages = {157--168},
doi = {10.1021/acs.accounts.2c00735}
}
EUVIMED